Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

European Journal of Cancer

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/j.ejca.2018.11.015

License

CC-BY-NC-ND

Other Formats

PDF